Semaglutide, Tirzepatide and Retatrutide: Single, Dual and Triple Receptor Agonism

Semaglutide, tirzepatide and retatrutide are often grouped together, but their receptor targets and evidence histories differ. Semaglutide activates the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide is being investigated as an agonist at GIP, GLP-1 and glucagon receptors.

The words single, dual and triple describe receptor targeting—not a scale that automatically ranks effectiveness or safety. Nor should the molecules be renamed “GLP-1,” “GLP-2” and “GLP-3.” GLP-2 is a different biological signal, not a shorthand for tirzepatide.

What changes at the receptor level?

A receptor is a cellular protein that responds to a particular signal. An agonist activates that receptor, initiating downstream responses. Knowing which receptors a molecule engages supplies a mechanistic starting point; it does not tell us the size of a clinical effect without measurements in people.

Semaglutide acts through the GLP-1 receptor, with effects relevant to appetite regulation, food intake and glucose control. The EMA’s Wegovy assessment provides regulatory and product-information context. Its conclusions concern the evaluated medicine and defined indications, not every product bearing the semaglutide name.

Tirzepatide is one molecule with activity at two receptor systems, rather than a mixture of semaglutide and a separate GIP product. The EMA’s Mounjaro assessment describes that dual activity and the authorized medicinal product. GLP-1 and GIP are incretin hormones: their physiological roles include linking nutrient intake to insulin secretion.

Retatrutide adds glucagon-receptor activity. Glucagon is not an incretin, so “triple-receptor agonist” is more accurate than “triple incretin.” Glucagon signalling participates in energy and glucose metabolism, but adding this target does not mechanically guarantee greater weight reduction or a better overall benefit–risk balance.

This is a pharmacology comparison, not a ranking of research products.

A direct comparison is more informative than separate headlines

SURMOUNT-5 directly tested tirzepatide against semaglutide in 751 adults with obesity without type 2 diabetes. It was a randomized, open-label phase 3b trial: assignment was randomized, but participants and investigators knew which intervention was being used.

The trial compared maximum tolerated subcutaneous tirzepatide at 10 or 15 mg with semaglutide at 1.7 or 2.4 mg. These are study-treatment details, not administration instructions. At 72 weeks, estimated mean weight changes were −20.2% and −13.7%, respectively—a 6.5-percentage-point difference within this trial. Gastrointestinal events were the most common adverse events in both groups. SURMOUNT-5 primary report.

Randomization matters because it reduces systematic differences between the groups at the outset. Both interventions were evaluated within the same eligibility criteria, follow-up period and assessment framework. That makes the comparison more defensible than placing results from unrelated trials side by side.

Its conclusion nevertheless has boundaries. Greater average weight reduction under these conditions does not establish superiority for every clinical outcome, for people with diabetes, or for other formulations. The open-label design is also relevant when interpreting treatment experience and discontinuation, even though body weight is an objectively measured endpoint.

Why the population and analysis belong beside the percentage

STEP 1 enrolled 1,961 adults with obesity, or overweight with an associated condition, without diabetes. At 68 weeks, semaglutide produced a mean weight change of −14.9%, compared with −2.4% for placebo, under the treatment-policy analysis. Both groups received lifestyle intervention. STEP 1 primary report.

A treatment-policy analysis addresses the assigned intervention while accounting for events such as discontinuation, rather than simply asking what happened among those who remained on treatment. It is therefore not interchangeable with an analysis designed to estimate an effect assuming continued adherence.

Retatrutide’s double-blind phase 2 obesity trial involved 338 participants. Its primary assessment was at 24 weeks, with further follow-up through 48 weeks. In the 12 mg group, least-squares mean weight changes were −17.5% at 24 weeks and −24.2% at 48 weeks; corresponding placebo changes were −1.6% and −2.1%. Gastrointestinal adverse events and heart-rate changes were also reported. Retatrutide phase 2 primary report.

Those results establish a signal in that study. They do not supply a randomized comparison against either semaglutide or tirzepatide.

Retatrutide evidence now extends beyond phase 2

The July 23, 2026 Lilly update reported TRIUMPH-2 and TRIUMPH-3 topline findings and described a planned first-quarter 2027 FDA submission. That release remains useful development-history context, not an approval announcement.

By the October 25, 2026 review cutoff, full phase 3 publications were available. The September 29 TRIUMPH-1 report described 2,339 participants with obesity without diabetes over 80 weeks, with a 28.3% reduction at 12 mg under the efficacy estimand. TRIUMPH-1 primary publication.

The accompanying Lilly results announcement also discussed the Lancet TRIUMPH-2 publication in type 2 diabetes. Its reported overall 12 mg reduction was 20.8%; the 23.4% figure concerned the subgroup with BMI at least 35, not the overall trial population. These sponsor summaries must remain distinguishable from primary publications and from treatment-regimen estimates that include discontinuation.

Read the comparison without turning it into a league table

Receptor biology explains why these are different interventions. Trials establish what happened in particular populations under particular conditions. Neither more receptor targets nor a larger percentage from a separate study establishes universal superiority.

The individual articles on semaglutide, tirzepatide and retatrutide develop those evidence histories separately. Authorization applies to specific medicines and uses; research products are not interchangeable with those medicines or with clinical-trial materials.

Reviewed October 25, 2026.